FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169456716> ?p ?o ?g. }

• W2169456716 endingPage "2732" @default.
• W2169456716 startingPage "2723" @default.
• W2169456716 abstract "The merozoite surface protein-3 long synthetic peptide (MSP3-LSP) comprises the amino acid sequence 186-276 of the Plasmodium falciparum protein MSP3. It is currently in development as an erythrocytic stage (blood stage) malaria vaccine candidate. We report here the first data on the safety, reactogenicity and immunogenicity of three doses of MSP3-LSP, adjuvanted with aluminium hydroxide, in healthy male adults living in a malaria endemic area.A phase 1b single-blind controlled trial was performed in the village of Balonghin in Burkina Faso. Thirty male volunteers aged 18-40 years were randomised to receive either three doses of 30 microg MSP3-LSP or 0.5 ml of tetanus toxoid vaccine. The second and third vaccine doses were given 28 and 112 days after the first dose. We followed participants for 1 year.There were no serious adverse events in either vaccine group. In both groups participants reported local reactions at the site of injection when compared to an earlier trial in European volunteers. Only one systemic adverse event (tachycardia) was identified which occurred immediately after the first vaccination in one individual receiving MSP3-LSP. No clinically significant biological abnormalities following vaccination were observed. Humoral immune responses (IgG, IgG subclasses, IgM) to MSP3-LSP peptide were similar in the two groups following vaccination. Some cell-mediated immune responses appeared to differ between the two vaccine groups. After the second dose of MSP3-LSP, there appeared to be a marked increase in the lymphocyte proliferation index and IFN-gamma in response to stimulation with MSP3-LSP.These data suggest that three doses of 30 microg MSP3-LSP when administered subcutaneously on days 0, 28 and 112 are well-tolerated by adult males previously exposed to natural P. falciparum infection. They also suggest that MSP3-LSP is able to stimulate an enhanced cell-mediated immune response in individuals with some degree of preexisting immunity." @default.
• W2169456716 created "2016-06-24" @default.
• W2169456716 creator A5007866259 @default.
• W2169456716 creator A5008604633 @default.
• W2169456716 creator A5010782141 @default.
• W2169456716 creator A5013139296 @default.
• W2169456716 creator A5014931823 @default.
• W2169456716 creator A5024619166 @default.
• W2169456716 creator A5040533373 @default.
• W2169456716 creator A5040772126 @default.
• W2169456716 creator A5051790261 @default.
• W2169456716 creator A5057357980 @default.
• W2169456716 creator A5059437494 @default.
• W2169456716 creator A5060392132 @default.
• W2169456716 creator A5073782786 @default.
• W2169456716 date "2007-03-01" @default.
• W2169456716 modified "2023-10-17" @default.
• W2169456716 title "Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa" @default.
• W2169456716 cites W190349426 @default.
• W2169456716 cites W2029705197 @default.
• W2169456716 cites W2038910210 @default.
• W2169456716 cites W2067559517 @default.
• W2169456716 cites W2069038428 @default.
• W2169456716 cites W2074122062 @default.
• W2169456716 cites W2086004205 @default.
• W2169456716 cites W2087667054 @default.
• W2169456716 cites W2126082637 @default.
• W2169456716 cites W2139338343 @default.
• W2169456716 cites W2139533311 @default.
• W2169456716 cites W2143319864 @default.
• W2169456716 cites W2164128190 @default.
• W2169456716 cites W2166262629 @default.
• W2169456716 cites W2167286092 @default.
• W2169456716 doi "https://doi.org/10.1016/j.vaccine.2006.05.090" @default.
• W2169456716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17280744" @default.
• W2169456716 hasPublicationYear "2007" @default.
• W2169456716 type Work @default.
• W2169456716 sameAs 2169456716 @default.
• W2169456716 citedByCount "52" @default.
• W2169456716 countsByYear W21694567162012 @default.
• W2169456716 countsByYear W21694567162013 @default.
• W2169456716 countsByYear W21694567162014 @default.
• W2169456716 countsByYear W21694567162015 @default.
• W2169456716 countsByYear W21694567162016 @default.
• W2169456716 countsByYear W21694567162017 @default.
• W2169456716 countsByYear W21694567162018 @default.
• W2169456716 countsByYear W21694567162019 @default.
• W2169456716 countsByYear W21694567162020 @default.
• W2169456716 countsByYear W21694567162021 @default.
• W2169456716 countsByYear W21694567162022 @default.
• W2169456716 crossrefType "journal-article" @default.
• W2169456716 hasAuthorship W2169456716A5007866259 @default.
• W2169456716 hasAuthorship W2169456716A5008604633 @default.
• W2169456716 hasAuthorship W2169456716A5010782141 @default.
• W2169456716 hasAuthorship W2169456716A5013139296 @default.
• W2169456716 hasAuthorship W2169456716A5014931823 @default.
• W2169456716 hasAuthorship W2169456716A5024619166 @default.
• W2169456716 hasAuthorship W2169456716A5040533373 @default.
• W2169456716 hasAuthorship W2169456716A5040772126 @default.
• W2169456716 hasAuthorship W2169456716A5051790261 @default.
• W2169456716 hasAuthorship W2169456716A5057357980 @default.
• W2169456716 hasAuthorship W2169456716A5059437494 @default.
• W2169456716 hasAuthorship W2169456716A5060392132 @default.
• W2169456716 hasAuthorship W2169456716A5073782786 @default.
• W2169456716 hasConcept C159047783 @default.
• W2169456716 hasConcept C197934379 @default.
• W2169456716 hasConcept C203014093 @default.
• W2169456716 hasConcept C22070199 @default.
• W2169456716 hasConcept C2777351567 @default.
• W2169456716 hasConcept C2777704310 @default.
• W2169456716 hasConcept C2778048844 @default.
• W2169456716 hasConcept C2778371730 @default.
• W2169456716 hasConcept C2779841045 @default.
• W2169456716 hasConcept C2780868878 @default.
• W2169456716 hasConcept C2781034427 @default.
• W2169456716 hasConcept C3017875465 @default.
• W2169456716 hasConcept C71924100 @default.
• W2169456716 hasConcept C86803240 @default.
• W2169456716 hasConcept C8891405 @default.
• W2169456716 hasConcept C98274493 @default.
• W2169456716 hasConceptScore W2169456716C159047783 @default.
• W2169456716 hasConceptScore W2169456716C197934379 @default.
• W2169456716 hasConceptScore W2169456716C203014093 @default.
• W2169456716 hasConceptScore W2169456716C22070199 @default.
• W2169456716 hasConceptScore W2169456716C2777351567 @default.
• W2169456716 hasConceptScore W2169456716C2777704310 @default.
• W2169456716 hasConceptScore W2169456716C2778048844 @default.
• W2169456716 hasConceptScore W2169456716C2778371730 @default.
• W2169456716 hasConceptScore W2169456716C2779841045 @default.
• W2169456716 hasConceptScore W2169456716C2780868878 @default.
• W2169456716 hasConceptScore W2169456716C2781034427 @default.
• W2169456716 hasConceptScore W2169456716C3017875465 @default.
• W2169456716 hasConceptScore W2169456716C71924100 @default.
• W2169456716 hasConceptScore W2169456716C86803240 @default.
• W2169456716 hasConceptScore W2169456716C8891405 @default.
• W2169456716 hasConceptScore W2169456716C98274493 @default.
• W2169456716 hasIssue "14" @default.
• W2169456716 hasLocation W21694567161 @default.

• next